2 active not recruiting, 2 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Recruiting 2 |
Follow DualityBio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer BNT324, Docetaxel, Prednisone/prednisolone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | BioNTech SE | 736 | 2026-04-22 | 2026-10-16 |
| A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer BNT323/DB-1303, Doxorubicin, Paclitaxel - Endometrial Cancer | Phase 3 | Recruiting | BioNTech SE | 480 | 2025-06-10 | 2026-10-16 |
| A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer DB-1303/BNT323, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Active not recruiting | DualityBio Inc. | 228 | 2024-01-29 | 2026-10-30 |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) DB-1303/BNT323, Capecitabine, Paclitaxel - Metastatic Breast Cancer | Phase 3 | Active not recruiting | DualityBio Inc. | 541 | 2024-01-18 | 2026-09-24 |
Breast Neoplasms (2) · Endometrial Neoplasms (1)
Docetaxel (2) · Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · Capecitabine (1) · Doxorubicin (1) · Prednisolone (1) · Prednisone (1)
China (4) · Australia (3) · Belgium (3) · Germany (3) · Poland (3) · United Kingdom (3) · United States (3) · Argentina (2) · Canada (2) · France (2) · Hungary (2) · Israel (2) · Italy (2) · South Korea (2) · Spain (2)
Joyce O'Shaughnessy, PHD (1) · Lily Hu (1)
2023 (1), 2025 (1)